Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

IGM Biosciences has decided to halt development of imvotamab and IGM-2644, two IgM-based bispecific antibody T cell engagers for autoimmune diseases, and cut its staff by 73%. The biotechnology ...

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including lupus.

both IgM-based bispecific antibody T cell engagers, for autoimmune diseases. Imvotamab or CD20 x CD3 is a bispecific IgM antibody that targets CD20 and CD3 proteins. It has 10 binding units for ...

By day 28, the titer of specific antibodies ... IgM (Fig. 2). The adjuvant works equally well for all mammalian species tested (mouse, rabbit, goat and swine). A slightly changed version of the ...

IGM Biosciences (IGMS – Research Report) received a Sell rating and a $2.00 price target from Morgan Stanley analyst Michael Ulz today. The ...

Bank of America Securities analyst Charlie CY Yang maintained a Hold rating on IGM Biosciences (IGMS – Research Report) today. The company’s ...

“I want to thank our colleagues who will be departing from IGM as part of the restructuring and acknowledge their many contributions to our programs,” added Dr. Harler. “We are grateful for ...